Tumor-promoting function of NPAS2 is dependent on HIF-1A activation and the engagement of glycolysis-related genes, indicating that NPAS2 may serve as an important therapeutic target to normalize glucose metabolic aberrations responsible for PCa progression. Here, NPAS2 is linked to neoplasm.